PT Kalbe Farma Tbk

As of June 30, 2026, PT Kalba Farma TBK carries a market capitalization of 1.80B, placing it among publicly traded companies globally. Its enterprise value stands at 1.65B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

PT Kalba Farma TBK's next confirmed earnings release is scheduled for November 3, 2026.

As of June 30, 2026, PT Kalba Farma TBK has 45.25B shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, PT Kalba Farma TBK maintains a current ratio of 3.15, meaning it holds 3.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026. Inventory turnover of 3.16 indicates how many times PT Kalba Farma TBK sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, PT Kalba Farma TBK recorded 45.31M in income tax expense.

As of the close on August 20, 2026, PT Kalba Farma TBK's stock has declined approximately 45.30% over the past 52 weeks. The 50-day moving average sits at 0.10, while the 200-day moving average is 0.11.

These figures cover the twelve months ended June 30, 2026.

As of June 30, 2026, PT Kalba Farma TBK holds 277.62M in cash and equivalents against 45.96M in total debt, resulting in a net debt position of -225.46M. Total book value stands at 1.35B, with working capital of 797.95M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, PT Kalba Farma TBK paid dividends of -NaN per share.

PT Kalba Farma TBK's most recent stock split took place on October 8, 2012 with a 1:5 split ratio.